Merck's Keytruda nabs melanoma nod in EU; AstraZeneca's MEK inhibitor fails late-stage melanoma trial;

> Merck ($MRK) won European approval for its closely watched cancer immunotherapy Keytruda, for use in patients with advanced melanoma who haven't yet been treated or who've failed on previous therapy; the drug won U.S. approval last year. Release

> AstraZeneca ($AZN) said its new cancer treatment selumetinib, a MEK inhibitor, fell short in a Phase III trial in uveal melanoma patients; testing is ongoing in a variety of other cancer types. Release

> With HIV treatments readily available in low-income countries, Doctors Without Borders is shifting its attention to broadening access to the meds in middle-income countries where cut-rate generic programs don't apply. Release

> Patients using the diabetes drugs Avandia (rosiglitazone) and Actos (pioglitazone) had a 28% lower incidence of Parkinson's disease, a study found; researchers said the results should prompt new studies into the drugs' mechanisms. Report

> Merck broadened its nanobody medicines collaboration with Belgium-based Ablynx, adding 12 new programs and boosting the total potential milestones to about 4 billion euros. Report

And Finally... The first U.S. drug delivery by drone happened in Virginia, in a test of the technology for transporting medical supplies to remote areas. Report

Suggested Articles

Sanofi's Sarclisa is coming full-force at Johnson & Johnson blockbuster Darzalex in the multiple myeloma field—now backed by new data.

Merck CEO Ken Frazier has spoken passionately about racism before. Monday, amid protests over George Floyd's death, he made that passion personal.

BMS is pricing Zeposia at the wholesale acquisition cost of $86,000, lower than the tag on Novartis' in-class rival Mayzent.